Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed.

Clinical and experimental dermatology

Volumn 31, Issue 1, 2006, Pages 143-

  Belgi, A S ^a   Azeez, M ^a   Hoyle, C ^a   Williams, R E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; CASE REPORT; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; LETTER; PEMPHIGUS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; METHYLPREDNISOLONE; PEMPHIGUS; TREATMENT OUTCOME;

EID: 33646095268     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01941.x     Document Type: Letter

References (0)